Please complete the CAPTCHA to continue
@dsi.com
✓
LinkedIn matched
A concise factual answer block for searchers comparing this professional profile.
Craig Gibson is listed as Global Value and Market Access Strategist at Daiichi Sankyo US, based in Greater Boston, United States. AeroLeads shows a work email signal at dsi.com and a matched LinkedIn profile for Craig Gibson.
Craig Gibson previously worked as Head of Global Pricing, Reimbursement and Access Oncology at Daiichi Sankyo Us and Global Market Access and Pricing lead at Alnylam Pharmaceuticals. Craig Gibson holds Ph.D., Cellular And Molecular Physiology from Yale University.
This section adds company-level context without repeating Craig Gibson's masked contact details.
AeroLeads found 1 current-domain work email signal for Craig Gibson. Compare company email patterns before reaching out.
I am a data-driven value and market access strategist and scientist, a cross-functional team leader with global experience in both commercial and medical sides of payer engagement.I have worked on successful access and reimbursement strategies for >25 products, across 30+ countries, and am dedicated to taking a long-term view in securing reimbursement for products that will meaningfully improve the lives of patients.
Listed skills include Pharmaceutical Industry, Lifesciences, Strategy, Market Access, and 19 others.
Company context helps verify the profile and gives searchers a useful next step.
A career timeline built from the work history available for this profile.
Basking Ridge, Nj, Us
Leading the Global Pricing, Reimbursement and Access team responsible for developing and setting the global strategic framework for pricing, reimbursement and access across the oncology portfolio, including marketed and pipeline opportunities.
Cambridge, Massachusetts, Us
Initially Global Pricing and Access lead for ONPATTRO, vutrisiran and TTRsc03. Expanded global role to include all marketed and pipeline products. Additionally acted as Canada Market Access leading HTA submissions and payer negotiations.
Waltham, Massachusetts, Us
Member of Global Clinical Development Leadership Team and Clinical Trial Review Board, reporting to the CMO. Took over VP-level duties to oversee all global: payer value strategy and positioning, early price assumptions, and evidence generation within and outside of clinical programs to ensure reimbursement/access to all TESARO agents.Managed team of 6, including: Head of US Field Value for communication to external stakeholders; Product Leads for key assets; and evidence generation experts
Waltham, Massachusetts, Us
Member of Global Clinical and Commercialization teams. Led global payer and evidence strategy for TESARO’s immuno-oncology franchise, including dostarlimab (α-PD-1 mAb), TSR-022 (α-TIM3 mAb), TSR-033 (α-LAG3 mAb) and TSR-075 across all indications. Proposed a new indication sequencing strategy that could increase annual European revenue for a portfolio asset by >$400M. Approach was included in planning for two early assets.
Summit, New Jersey, Us
Led Global Market Access, Pricing and HEOR for CAR-T programs (JCAR015, JCAR017 collaboration with Juno, bb2121 collaboration with BlueBird Bio); access rep to Global Project Teams and involved directly with partner companies on strategic direction and alignment.Hosted cross-functional workshop to identify payer data gaps and possible funding pathways for CAR-T therapies in Europe, including alternative payer pathways for access to highly specialized therapies, such as: HST pathway in UK, innovation funds, impact of hospital exemption in EU.
Summit, New Jersey, Us
Led Global Market Access, Pricing and HEOR for Multiple Myeloma (MM) Franchise (Revlimid, Pomalyst/Imnovid, Thalomid), managed team of two FTEs and several interns, and was the Access rep to Global Marketing/Medical/Market Access strategy team for Revlimid. • Access planning and communication lead for 3 global launches in 3 years, including: Payer value story and value communication; Global value dossier and economic models; global price guidance and contracting tool.• Author on 7 manuscripts and 21 conference abstracts (including 6 oral presentations) in 3.5 years.
Summit, New Jersey, Us
Paris, France, Fr
Led Global Market Access for transplant portfolio (Thymoglobulin and Mozobil), and Zaltrap in colorectal cancer (ex-US), worked with country affiliate teams to provide guidance and review of P&R and access plans.•Developed, gained Sr. management buy-in, and began implementation of integrated pricing strategy for Thymoglobulin (including selected withdrawal) that increased revenue by >$4M.•Created and defended economic value story for BARDA BioShield proposal for Leukine, worth up to $250M.
Bonn, De
30+ projects for pharmaceuticals, biotech, and med devices including for oncology, CV, ophthalmology and hematology, focused on: peri-launch pricing, landscaping, trial design, market access, pricing and reimbursement, positioning, portfolio and product launch strategy in the Americas, Europe, and Japan.
Quick answers generated from the profile data available on this page.
Craig Gibson works for Daiichi Sankyo US.
Craig Gibson is listed as Global Value and Market Access Strategist at Daiichi Sankyo US.
AeroLeads has found 1 work email signal at @dsi.com for Craig Gibson at Daiichi Sankyo US.
Craig Gibson is based in Greater Boston, United States while working with Daiichi Sankyo US.
Craig Gibson has worked for Daiichi Sankyo Us, Alnylam Pharmaceuticals, Gsk, Tesaro, Inc., and Celgene.
You can use AeroLeads to view verified contact signals for Craig Gibson at Daiichi Sankyo US, including work email, phone, and LinkedIn data when available.
Craig Gibson holds Ph.D., Cellular And Molecular Physiology from Yale University.
Craig Gibson is listed with skills including Pharmaceutical Industry, Lifesciences, Strategy, Market Access, Life Sciences, Pricing Strategy, Oncology, and Market Research.
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial Search contacts